Chester County News and Community Website
WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for AstraZeneca’s supplemental Biologics License Application (sBLA) for IMFINZI® (durvalumab) in the treatment of …
AstraZeneca’s IMFINZI® Granted Priority Review for Early-Stage Gastric Cancer Treatment Read More
WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical data from its oncology pipeline at the upcoming European Society of Medical Oncology (ESMO) Congress, set for October 17–21 in Berlin. …
Incyte to Spotlight Next-Generation Cancer Therapies at ESMO 2025 Read More WILMINGTON, DE — AstraZeneca announced that its lung cancer therapy TAGRISSO® (osimertinib), when used in combination with chemotherapy, delivered a statistically significant and clinically meaningful improvement in overall survival for patients …
AstraZeneca’s TAGRISSO Combo Shows Strong Survival Benefit in EGFR-Mutated Lung Cancer Read More
CHESTER SPRINGS, PA — Curadh MTR Inc. and Alpha Fusion, Inc. are set to showcase advances in cancer treatment using Astatine-211 (At-211) radiopharmaceuticals at the upcoming 4th Targeted Radiopharmaceuticals Summit …
Curadh MTR and Alpha Fusion to Spotlight Breakthrough Cancer Therapy at Radiopharmaceutical Summit Read More
WASHINGTON, D.C. — The U.S. Food and Drug Administration (FDA) recently announced it has eliminated the Risk Evaluation and Mitigation Strategies (REMS) requirements for all currently approved BCMA- and CD19-directed …
FDA Removes REMS Requirements for CAR T Cell Therapies, Boosting Patient Access Read More
DOYLESTOWN, PA — Aprea Therapeutics, Inc. (Nasdaq: APRE) has revealed new preclinical findings and a clinical update on APR-1051, an innovative oral WEE1 inhibitor being studied for the treatment of …
Aprea Therapeutics Announces Promising Data on APR-1051 for HPV-Positive Cancers Read More WILMINGTON, DE — The U.S. Food and Drug Administration (FDA) has approved Monjuvi® (tafasitamab-cxix) in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory …
FDA Approves Monjuvi for Treating Relapsed or Refractory Follicular Lymphoma Read More WILMINGTON, DE — The Phase III MATTERHORN trial has delivered groundbreaking results, demonstrating that AstraZeneca’s IMFINZI® (durvalumab) combined with FLOT chemotherapy significantly improves outcomes for patients with resectable early-stage and …
MATTERHORN Trial Reveals Promising Results for Early Gastric Cancer Treatment Read More
KING OF PRUSSIA, PA — SK Life Science Labs, a subsidiary of SK Biopharmaceuticals Co., Ltd., has announced a major advancement in oncology with the discovery of PVTX-405, a potent …
SK Life Science Labs Unveils Breakthrough in Cancer Therapy with PVTX-405 Read More WILMINGTON, DE — High-level results from the DESTINY-Breast09 Phase III trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), in combination with pertuzumab, significantly improves progression-free survival (PFS) compared to the current 1st-line …
ENHERTU Combination Shows Promising Results in HER2-Positive Metastatic Breast Cancer Trial Read More